| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
No Severe Long-Term Toxicities With 2-Year Local Recurrence-Free Survival At 77%
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks afte...
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Piper Sandler analyst Jason Bednar reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and lowers the price target ...
